REGISTERED COMPANY NUMBER: 07564771 (England and Wales) RECJSTERED CHARITY NUMBER: 1141583 GE.NE. PECPLE the genetic conditions support network GEr4E PEOPLE Unaudlted FlnanelAI StatetThents for the Year Ended 31 March 2024 XeinadiIi Nightiti8ale House 46-48 E8$t Street Epsom Surrey KT17 IHQ GENE PEOPLE Our vision is that anyone affected by a genetic condition receives the support and inforniation they need at the time they need it and in a forni they can use. Together, We are Gene People. GENE PKOPL Contents of the Flnancl81 Statements for the year ended 31 M4reh 2024 Page Referenc¢ 8nd AdJnlD15tr8tlve Delalls Report of the Trll$tee$ 2 to 7 tlldependent Examlner's Report Statemellt of Acllvltle8 Balance Sheet io Notes to tb¢ FlnAn¢lAI Sthtemellts 11 to 17 Det&lled Statemellt of FIDanclal Aetlvltles 18 GENE PEOPLE Reference and AdD￿nIStrA11ye Detsllg for the year ended 31 Mar¢h 2024 TRUSTEES DrCRuff S Mitrd AJKent D Ansel C J Conway Dr N V Tav£rn¢r D G Atkins (resigned l.11.24) Ms A Pakl (appoitited 24.6.23) C A Steward Director (appointed 31.1.24) N L Nic1￿lIS Di￿t0￿ {appointed 19.3.24) REGISTERED OFFICE Ni8htinga16 House 4648 Fast Strtti Epsom Surrey KT17 IHQ REGISTERED COMPANY NUMBER 07564771 [EngI￿]d gnd Wales) REGISTERED CHARITY r4UMBER 1141583 INDEPENDENT EXAMINER Xeinadin Nightillgale House 4￿8 East Street Surrey KT17 IHQ SOLICITORS Stone King LLP. Bowidary Hou 91 Charterliouse Street Barbican Londo ECIM 6HR BANKERS Barclays CorpDrate, Level 27. 1 Chllrchill Pl&c¢ ￿ndon, E14 5HP Poge I GENE PEOPLE (REGISTERED NUMBER: 07564771) Report of the Trusteej for the year ended 31 Mftreh 2024 The trllstees who ore also directots of the eharity for the purposes of the Compantes Act 2006, present their report with the flnancial statements of the charity for the year eThded 31 March 2024. The ttustees have adopted the proYisioJ)s of Ac¢ounting and Reportillg by Charities.. Slatement of Reeommended Practice 8ppli¢able to charities preparing their accounts in a￿OrdanCe with tbe Financial Reporting StaDdard applicable ¢he UK and Republic of Ifflaod IFRS 102) (effective l January 2019)- Welcome from the Chllr Tlus year has not been an easy one for many thousands of families living with a rare genetic disease. Finding expert help from the NHS is still a struggle for mony. Getting a diagnosis can often be a tortuous pmcess involving frequent hospital visits and appointment5 With ditTerent doctOTS. Even Atl¢r a diagn0515 setting tlnlEly atld user-friendly belp aud support 15 by no means certain. For an ine￿a9*ng number of families struggling to navigate the NHS maz¢ Gene People's unique genetic cO￿nstI10r led helpline provides a lifeline. fainilEes and supporting them iD r]ndintsF the belp they need. This yearwe have seen a increase in the complexity of t]ie issues farnilies calling the helpline are facing. Ofteii these are not just inedical questions. Finding educational and social support, mon¢y worries alld the impact OJJ other family members all add io th¢ burden fai￿111¢S face. We do whot we can to help* atld the feedback we reeeive demonstrates how much this is appreciated, but our tesources are limited. Wlth more we could do more! Our Phrtn¢rship N¢twork contiimes lo expand. During ihe y¢arw¢ have run ¢vents to trnin and supp)rt the members of the Netwoik in¢rea5e their rffectiveness IA helping'theirf, fainilses &nd argue the case for greater awftreness of their specific needs. This aspect of our work links in with Gene People's policy focused advotacy. During the year wc have provided expert input 8nd cornmentary to an increasiDg nllmber of OovernTnent and NHS consultations, p￿tting the needs and views of our cornmunity firnily in the fTom¢ for the attention of policy maker8 andplanner8. Our focus is not restricted to Govemmtnt and tbeNHS. We ilso engage witb induity through the ABPI, the BIA and with illdividual cO￿Panies, and ¢ollalJoral¢ with Charity partners wher¢ ourpriorities oY¢rlap. Th¢ synw this gellerd(es b005t8 our imp8¢t 5ignific8ntly. We h#ve seen A growing &wareT￿8 of the impaet on the mental bealth of those with a rare genetic disorder and on their familie5 during the year. tbis is a welwllje developnient is sornething we have been prO￿OI]ng for Some time. During the yeAr Gene People has undertaken a number of important projects supported by, amongst others, Genomics England, LifeArc and industry sponsors. Details of these are elsewhere iti this rtport. Thest are tangible proof of (trur growiiig impacl as a valued ￿rtIleE jll the developn]¢nt of effective help and 514)port for all those liv￿n8 with wimet need5 arising frorn a rare gelletic condition. None of tliis would hive been p055ible without tbc t1￿]e$S woik of our smill staff team, tlie guidance and s￿p￿rtof my frllow tru8t¢¢s alld tb¢ IAput frottt volunt¢er8. My thank$ to you all foryour dedication and hard work E must also thank all those who have supported Gene People financially during the year. We are grAteful, for without this oihing would bE POSsibl¢. oking ahead, IheTe is inu¢h to be doll¢. but l am coJfid¢nt thfyt we will rise to tbe clwlleng￿ we face and ¢oJ]tinuc to provide a voice for our community that will be heard by those wlth the opportunity to bring about tbe changes we seek. Ala¥lairKellt OBE FRSA Chairof thst¢¢s Pag¢ 2 CENE PEOPLE (REGISTERED NUMBER: 07564771) Report of the Trustees for the year ended 31 Mareh 2024 OBJECTIVES AND ACTIVITIES Objectlves aud alms Gene People has a vision io improve th¢ lives of those affe¢ted by a genetic condittoii through the provision of resource8 and support both to individuols and families. and to th¢ hundreds of ¢ondition-specifi¢ charities aNd pJti¢nt groups that have been es¢ablished in the UK. Th¢ objcctive8 of the clwity 8r¢'. To ￿lSe aw8toJ¢ss and advance the education of thE public on the subject of 8eneltc di50Tder5 The telief of persons suffering from genetic disorders The gdvancement of medical Tesearch into the cause% ￿re, preyention or relief of Such disorders and tlie publication of results of that research To promote th¢ ¢tYiciency and effectiveness ol other genetic disorder charities so they may achieve their charitable purposes. SIEnlfleAnt attl￿deS This year wa$ th¢ Second year of Anlplementing our strate8y. This is available ott our website to download on this page.. httys.-Ilgen¢peopl¢.org.vklabout-U51geRe-people-Sttate8y-2022-20251 Everything Gene People does Contributes to achieving three strategic pillars, all of which have beell designed to improve the lives of those living with geneti¢ conditions. The three pillars are.. - Support and Informfytioll - Str¢ngthertin8 condition-spe¢ifi¢ support groups and O￿niS8t10￿$ - AdvocAcy and eoll8boration. The Tmste¢s had set soine specifi¢ plans foi 2023-24. These w¢r¢- - Focw on income geKeiYJlioit fhrough increasing visibilEty.' while the thndraising environment is extremely challenging we are grateful to those who continue to support OUT work. Wc have spoken at and alieiided a Ivide iaftge of eywits iiJ¢luding the B￿ropean Society of Hum8n Qenelic8 conference, the ABPI Conferenee, and Life Sciences Walei Hub and webinars such as Meddigiial. Fo￿lS opj MakEng ilie voice of Ilved uperience inforniing slitylegic dlsetAs$io#s abotsl iiew ireulmeiits and reiipibiirsenient.. Gene People n￿l￿￿1￿5 a watchin8 briEf on NICE appraisals that affert OLIT coIllniuiJitie5 advvcates for lived experience lo be in¢ludd in de¢ision making. Coniliitse lo Ipxpyove optd develop ihe Helpll*e.' we have been interrogating the data we collect from ¢allers to thE helpline with support from LifeAr¢. A report on these findings will be published in 2025 will help to infonn our ne%¢ 8t¢ps in improving thÉ$ viial servi¢e. Hold regvlw. weblnars MngÉ of topicsfor ihe Purtheyship Nehyop'k.. we bcsan our next series of webinllrs tsn 'Influencing' which was kindly supported by the BJA Rare Diseases Industy Groiip. Unfortunately, th¢ sn8y Gelleral Election Meant a 51ighl hiatus in delivering this seri¢s and the flnal webinar of this series will take place in 2025. Hold ihe Gene People Leadgrsliip Syinposium.- this took place in November 2023 and is now h firn) r￿tUre in Gene People's work. Conlirtue lo seek inputfroin the Geiie People Pai'liieishlp Nehvoi'k Advisory Pavel.. this ￿ntInUed in 2023 and was pavsed in 2024 due to capacity issu¢s. Thi5 WLII b¢ reinsthted in 2025-26. Subniit responses to consulidlioiis wilh inpui froKi our PL7rlnErship Nefwork where possible.. Gene People has responded to inany and v8ried conwlialions not limited to those relating to health and Social CgTe but also Iliose of imporlance to charities as legal entitie& Our consultation Tespon8e$ b¢ found on our website wider 'National Policy.. W¢ r¢pr¢s¢ni tli¢ views of our¢ommunity at ¢vents, and arr a of a ran8¢ of organi5alio]]$ including.. - Association of the British Pharn)aceutical Industy Palient Org8nisatÈonFotYm - Breaking Down Barriers - NIHR O¢iieli¢s NSO Clit]iral Reference Network- now disban¢kd - Disabled Childr¢n's Partnership GeJetic Alliance UK - Pres¢riplion Charges Coalition Specialised Health Cate Alliance - NICE Voluntary and CoD]Tllunity Sector fiollittL Page 3 GENE PEOPLE (REGISTERED NUMBXR: 07564771) Report of the Trustces for Ihe year ended 31 Mférch 21124 The team have actively coDtributed to events and meetings orgatiised by these grollps as s￿aker, chair or facilitator. In additiott, Gene People has eiigaged actively wilh= - Association of Genetic Nurses and Coun$ellors British Society for Genetic Medicine - F.uropean Rare Dise85e Helpline Network Pllblic Poliey Projects - Ro8ld Dabl Maryellous Children's ChArity. Gene People is now representing the needs of our commu[Liti￿ on the ABPI Patient Advisory Council. These activities look place alongside the core business of the Helpline, fijndrydisitig 2nd running the charity. To focus the helpline briefly, this y¢ar the Gen¢ People g¢ll¢iic counsellor led helpline responded to 156 enquiries from individuals, familaes and professionals dealing with a gettelic ¢ondili071. Our ¥enetlL LOUll5¢11or spent 71 hours Qll SUPPI)rt cAII$ and sent 248 support emails. Enquirers most often contacted the helpline about genetic testing (28*10) and for guidance on how to access clinical geneliG seTvi¢es (250/o}. Emotional support wa5 ofteD n¢eded, ond all eiiquiries were IDanaged with sensitivity and eare. Enqiiiri¢$ wer¢ nkad¢ al)out 97 differellt geEJcli¢ coijditions. with Cystic Fibrosis b¢%ng tlie iDosI common eoDditio enquired about. Many other conditions wer¢ only enquiTed about on one occasion ea¢h And are extremely rare diseases. Some of ihe situations managed were eomplex and required ongoiÈJg 5UPPOrt from the helpline genetic counsellor. Ottr ongoing pre 2nd post contACt impttct suryrys showed that IOOOA of those enquirets who resptsnded found theirconlact with the service helpful. Some of tlje feedbadc received included: 'Thank you so much for your email which providEd us with lots of clarity and inforniationl It wlly h¢lped u5 make sense of everythin8 and think about options moying forw&rd. We think tt's amaxing th¢ work Gene People and people like yOUT5elf do." "It ivas a breath of fresh air talking to Emily who was en)pathic Ind ill¢r¢dibly inforniatiY¢. I found out more obout my child's cottdition thaii I glearted from the 8encticist who 82Ye us the diagnosis. Emily 1$ very approachable and as such I felt able lo sk questions I had been unable to ask Anybody else. She sent through some brilliant links afterwardg about my child's ¢oiidilion attd s&id that T can contact her anytime. Jnvaluablel Thank you SD much Gene People" All of this woik is llDI possible without the kind support of generous donors 8nd fvnders. While the fundraising ¢JJYironmellt is Chpllenging, Gene P¢opl¢ is delighted to have been supported in 2023-24 by.. Adelphi Genetics Fon]m An)i¢us Therapeutics - Thc D'oyly Cartc Charitable Trust - Eg¢tis Th¢rapeutios - GiYeA5YouLive givers LifeArc - London Marathon Runllers PaTcxcI International Regular givers - UK Bio tndyslry Association Rare Disease Industry Group - Alld all thosE who p￿f¢r to r¢main awnyjnous. Ev¢ryone at Gen¢ People 18 deeply grateful for the support. Together, we are Gene People. LAstly, following the adoption of ￿ Environmentkl policy whi¢h in¢lude$ 8 public ststem¢nt of oiir ¢8Tbon emi58ions. OureIDissions for fmattcial year 2023-24 were 0.83 tonncs o£C02¢. Pmbllc benefit The t2UStees confinn that they have eon)plied with the duty in Section 17(5) of the Charities Act 2011 io hayc dlle regard to the guidanct issued by the Charity Commissioll on pvblic beDefil. The charitable pury)ose for the charity withiij the tneaning of th¢ Act is ¢nshrilled within its objects. os giY¢n in ihe memorandum and articles of association, 8t￿ th¢ charitable objects ar¢ included io this report. Page 4 GENE PEOPLE (REGISTERED IYUMBBR: 07564771) Report of the Trustees for the yeai. ended 31 2024 FINANCIAL REVIEW R¢sErYe5 On 31 March 2024, the tot&1 monies held by Gene People stO(Kl at £23,369 of whicl) ￿$triC(ed fvDds WeTe £5.594 Free reserves, ps d¢fw¢d by th¢ Lharity Commission. were £17,775 The trllstees revi¢w¢d and revis￿ th¢ long-standing Teserve5 policy and are of the opiniort it is prudent to target approximAtely £25,000 in resetve. This reflects the Teduclion in size of the charity and provid¢s five months of &Yerage Tunhing costs, which trust¢¢$ ¢on$id¢r to be suffi¢ient to rc5pond to an unexpected eniergency or cover costs of an orderly wind-up should that be necessary in the fllb￿. Golng eoneern Gene People has for the first time in several years a¢hieYed a sutplu$. HoiYever> given the eost of living Cris￿8 and the impact this hgs had on every incomE stream Gene Peopl¢ hbs acc¢55 to. there hA5 beeD an anticipated fvrther decline in iDcome in 2023-24, therefore. the trustees have ssses5ed wh¢tbcr the us¢ of th¢ going wn¢ern ossumption is appropriate iii preparing these fllian¢ial 5tatem¢nts. The trustees have made this assessment using forecasts and budgets prepared to cover ¢h¢ period io March 2025. Ill considetillg 80iDg wncern for 2024-25, the tNstees have assessed the probability of successfully rgising the thttding requircd for ihe redllced ststTJn8 slrncture. Given th¢ continuing 8UPPOrt received froin cotyorales, funders and individuals anil the incffase in eamed income in thc cutrcnt fjnancial year to date, the twstees have oitrently a55es5ed that the charity it should continue to be regarded as a goit)g concem and therefore the financial staicmcnts includc no adju5ttnent this resp¢c¢. FUTURE PLANS Tli¢ Trustees Agreed the following strategic ain]s for 2024-25: - Maltitain foeui on income gcacr&tion through increasitig visibllity - Expalld diyersity of iiicome to include reve#ues earned through ¢ontracts - Continue to improve and develop thc Helpline - Hold regular webinars oll O Tange of iopics for the Partnership Network - Hold the Gene People Leadership Symposiijni - Submit r¢5pons¢s to ¢onsul¢alions with input from our Patlnership Network whcr¢ possibl¢ - Explore ways to both create effLcieDcy in ways of workng and bctleT SUPPOrt our individual donors. Poge 5 GENE PEOPLE OIEGISTERED NUMBER: 07564771) Report of the Triistees for the yelr ended 31 March 2024 STRUCTURE, COVERNANCE AND MANAGEMEf4T Gov¢rnlng docuJEiCnt The thartty is Controlled by its govemill8 doCU￿en( a d¢ed of tryst, and constitutes a limited company. limited by guarantee, as defined by the Companies Ael 2006. Gene People changed its name from Genetic Disorde￿ UK (GDUK) in May 2021. The regislgred charity number (nutnber 1141583) and company limited by b4]ThDtee (nuniber 07564771) remained the Same. Gene People is governed by its inemorttndum artd Articles of association dated 15 Mar¢h 2011. The ¢harity 15 controlled by its governing document. a deed of trust. and constitutes a limited company. limited by guar8ntee, as defined by the Companies Act 2006. Deelslon makln The board of twste¢s is TespoD5iblf for the overall governance* policy and strategic dijtction of Gene Pe4)plc, and havc the legal r&4pon$ibiltty for the operations of the charity and the use of resourees in occordance with th¢ obJ￿ts of the charity. The trustee9 who bave served during Ihc ycar and sincc thc ycar end ore sel out on page l. Th¢ charity is governed by individuals with a broad range of skills, inc1l￿ing biotech, operation5, finance alld charity rnonagemettt expertis¢. A personal petspeclive on what it is to be part of a fattiily 8ff¢¢t¢d by a genetic ¢ondition was provided by trt￿tte$ during the finan¢i81 year with further two tnLStee$ with lived experienc¢ of a condition as parents joiniiig durit]g the period following the ftnancial year. Governance And MAiiagernent Tn]5tees serve on tlie board for a pwiod of three years ¢hat is r¢newable. New trnstees are appointed by the serving trustccs, considcring the skills required by theboard. The l>oard of twstees meets at least four times a yeaT to review progr¢ss at￿ policies, With additional virtual meetings via video conferencing. With th¢ changes to the chaiity and the impact of the pandemic, meetings wett more frequent during the year. Forn)al r¢pDrting by the Chief exe¢utive to th¢ tru5tee5 t&ke5 pla￿ regularly at IM>wrd me¢tings alld infomially as appropriate throughout the year. The syslems of control that or¢ d¢5igned to provid¢ reasongble assurance against material misstatement or Ios5 include. an allnual budgel approved by the tn]stees' regular review or rin Jeans for Genes, merchandise sales Lnd inierest receivable. Donations and grants in respe¢t of charitable activities are reeognised when the charity lias Confimiation of both the amoiittt and SEltletnent d8te. th th¢ event of amounts pledged but not reeeived, the amount is accrued for wbett th¢ r¢¢eip¢ is ￿nSid¢red probable. In tbe evellt that a donation or gtllnt wbjecl to conditions that require l¢v¢l of p¢rfonn8nc¢ befor¢ the chatity 15 ¢nlLtld to the funds, th¢ snwm¢ is def¢Th￿ and not r¢cogllised until either those conditions are fiilly met Or the fiilfjlment of those conditions is wholly wiihits the control of ihe charity and Él is PFobable that those ¢olldition5 will be ￿lfilled in the rep)rting period Legacies are incliided in the slAtemenl of financial activities whell th¢ ¢harity 18 entitled to the legacy. tb¢ executors have established that there atc sufficient surylus ass¢ls ID the e4tate to pay the legacy and any condilions attllched lo the le88cy ale wiÉhin the ¢ontrol ofthe Charity. Entitlemellt is token as the earlier of the date on wbieh either.. the charity is awaie that probate has been granted: the ¢stste has beett finalised and iiotifieatioll has been n]ade by lh¢ ¢xe¢utor to Ilie charity th&t a distsibution will b6 ]nadE,' whBll a distribution is r¢¢¢ived from the estate. Receipt of a legacy, ill whol¢ or in p&rt, is only considered probabl¢ wh¢n th¢ amowjt Can be measured reliably and the charity ba8 b¢en notified of the ¢xe¢ulo￿$ intention to make a dislribulion. Where legacie$ httY¢ been notified to th¢ ¢hurity OT the charity is aware of the granting of probate, but the ¢ritsria for incorn¢ r¢cognition h¥Lve not been mel. then the legacy is treated as a conlia]gent as$¢t and di5clo$ed if nTrat¢rial, In the event that the gift is in the forni of atl asset otller than cash or ll financial asset traded on Ttcogtiised stock tx¢hange, recognition 15 subject to the Value of the gift b¢ing reliably m¢usurable with a degree ofreasonable accurncy and tbe tille of the asset hAving bccn transferred ￿ the eharity. Interest fund$ held on deposit 15 included when ￿ceIvAble and the amouiit cali be measured r¢li8bly by the charity. this is normally upon notification of the inlere5t paid vr payable by tli¢ bauk. EXPEf4DrruRE Liabilities are r¢¢ogni8cd a$ ¢xpondiftwe Js 500n as there is a legal or cons(tuctive obli8alioD co]nn]ittiDg the charity lo that expenditure. it is probabl¢ that a IrHnsfer of economic benefits will b¢ required in settlement and the Binount of the obligalion ean be ineasured ￿lIablY. Pag¢ll ¢ontitiued... GKNE PEOPL Notes to the Flnanclal Statements- eontlllucd for the year ended 31 March 2024 ACCOUNTINC POLICIES- ¢ontinued EXPF,IYDITURE Expendititre is accthinted for on 2ts accnjals b&si$, ex¢lusiYe of any VAT which is rccovcrablc, Direct costs attributable to U 8ingl¢ a¢tiYity are allocated directly to that activity. Shared costs, which contribute to more than one activity. and support costs, which are A)ol attributable to a single activity, are apportioned between those activiti¢5 oll & ba515 C01151Stellt with the use ofre50urces. Govemance costs in¢lude die costs incurred in the govemance of the charity and are primarily associated ivith consti￿¥10]1al and statutory requirements. Expenditure is only deferred when it relates to hture years. CFrattt$ awkrded are re¢ognised i¥h¢n the offer And amount of the Etsnt is conveyed to the beneficiATy. Grattts are paid in fvrtherance of the charitable obje¢tiv¢ of the charity. All expenditure is inclusive of irrecoverable VAT. RELATED PARTY EXEMPTION The chariLgbl¢ company has tsken advantag¢ of ex¢mp¢ion, ynder the tenns of Financial Reporting Stsndard 102 'The Financial Reporling Stsndard applicable in tbe UK and Republic of Ireland,, not to disclose i¢lAted paty IransACtiOE]s with wholly ommeil 5ubsidiarie5 Within lh¢ group. TAXATKON Thc ch&rity is ex¢mpt from corpora¢ion lax on its Ch￿ltrable activities. FUF4D ACCOUNTING Ullreslricted funds call be vs¢d Èn 4ccordanc£ with the ¢hpritabl¢ gbjextives 01 the discr¢lion of th¢ twste¢8. Restricted funds can only be used forparticulaT restricted pwposes within the objects of the charity- Restrictions arise when specified by the donor or when funds are raised for partioular restsieted purposes. The cost$ of raising and adjninistering such funds are cbarged against th¢ spe¢ifJ¢ fund. Further explanation of the nature and purpose of each fund is included in the notes to the finallci&l ststements. COINC CONCERN The accounts show5 slight increase in revenue in 2022-23, the ttuBtees have assessed that die use of going conttm 15 appropTiate in prepatiTrg Ilie5e fJnancial 51&teffienls. The ITu51ee5 haye made this asse5sTnent using forecasts and biidgcls prepared to coyer period to March 2024. In considering going concem for 2023-24, the trustees hRYe &sse5sed ihe profitsbility of success￿11Y Taising the n￿esSary funditlg through the fundtai5ing 5trat¢gy and ￿Tted thal re5erve5 could be used in thi5 qua5i-s(att-up phase for the refomied cliarity. Given the Mipport received from corpoiates, filndets and iiidividuals so far, Ihe tnislees ljave ¥sse$sed that charity should not be so affected by the Changes tljat it should not be Tegarded as a going c4)ncem and therefore the fin8n¢ial statements incliide no adjustmenl in this respect. BASIS OF CONSOLIDATION The Stat¢m¢tit of f￿a[￿claI ￿tiVItieS (SOFA) and balaw¢ sheet Consolidated tlJ¢ fEnancial st8tgm¢nts of th¢ charity and its subsidiary undcrtaking. The res111ts of ihe sllbsidiary are con80lidatcd on a line by line basis. No separate SOFA has been presented for the charity alone as pennitted by section 408 of the COM￿nicS Acl 2006. Fif4ANCIAL INSTRUMENTS The charity only ljas r]nancial assets attd financial liabilities of a kind that qualify as basic fujancial illstrutnents. Basic fin8nciol in5trninentS 8Te initially Tecognised ot trans&ction value and subsequently measured at their settlement value with the exception of bank loans, which are subsequently tneasured at amortised cost using the elYeciiv¢ int¢rt$t m¢ll￿d. Page 12 continucd... GE24E PEOPLE Notes to the Fln¥n¢lal Statem¢nts- contlnued for tho year ended 31 March 2024 DONATIOFIS AP4D LEGACIES 2024 2023 Donations OTHER TRADING ACTIVITJES 2024 2023 Ch&titable a¢tivitiE5 RAISINC FUNDS OTHER TRADINC ACTIVITIES 2024 2023 Stsff costs ProMolto￿l it¢￿5 16,505 39,236 CHARITABLE ACTIVITIES COSTS Support costs (8¢¢ note 6) Direct Costs Totals AwarcnEss alld ¢du¢ulion Relief 6,625 15,200 21,825 SUPPORT COSTS Govemance Costs Management Totals Aw&r¢ness and edueatio Relief 11,960 3,240 15.200 TRUSTEES, REMUNERATION AND BENEFITS There w¢re no Iruslees, remuneration or other benefits for tlie year ended 31 Mkr¢h 2024 llor foT the y¢ar elldEd 31 MaTch 2023. TRusfEES' EXPENSES There were no tA￿tees, ￿penSeS paid for the year etthd 31Mar¢h2024 nor for th¢ year ended 31 March 2023. Pa8¢ 13 continued... GENE PEOPLE Notes to the filnhnclal StAlementS- tontlnue for the year ettded JI MArch 21124 STAFF COSTS Staff eosl8 were as follows.. 2024 2023 WAges and salaries Social 5¢writy ￿sts Other pension cosL8 50,973 84.567 4,367 The average monthly number of employee5 duritig the yearwas As followg.. 2024 2023 Fundrdising Charitable The tsumber of employees whose employee benefits (exeluditig employer pension ¢osts) exceeded £60,0￿ was.. 2024 2023 £60,001- £70,(KJO The #ggtegate employee benefit8 paid to key managen]ent personnel were £32.347 (2023= £69,015). COMPAIL4TtVES FOR THE STATEMENT OF FINANCIAL ACTtvrriES Unrcslrieted fithd REStri¢ted ttdB Totsl fijnds INCOME AND fNI)OIVMENTS FROM Donations and legacies 108,008 EXPENDITiJRE ON Raising funds 56,492 56,492 ChgrltRble Acilvltle5 Awareness and education ReliBf 34,938 28,702 8,715 43,653 TotAI 120 132 128 847 IIET INCOMEI(EXPENDITURE) (14.124) (6.715) (20.839) RECONCILIATION OF FUNDS Total fvllds brought fojward 24,38S 6.715 31.100 TOTAL FUNDS CARRJED FORWARD Page 14 CODtiDued... GENE PEOPLE Note$ to the Flnttnclal Statem¢nts- continued for the year ended 31 March 2024 io. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR 2024 2023 Trade debtors Other debto] VAT Prepayments and accrued incom¢ 7,625 6,252 6,252 ii, CREDITORS: AMOUNTS FALLING DUE WITHIN 0Tr4E YEAR 2024 2023 Trade creditors Social security and other taxes Othercreditors A￿nI815 alld def¢Tr¢d itt¢om¢ 87 2,332 735 1.709 201 12. MOVEMENT IN FUNDS Nel mtsvanenl in fiEndg At 31.3.24 At 1.4.23 Unrestrlcted funds G¢neral futtd 10,261 7.514 17.775 R¢5trl¢*ed Symp05ium S,S94 5.594 TOTAL Fuf4DS Net movement in fi]nds, included in the above are as follows: Incomi￿g resources Resources expended Mov¢nienl in fimds Unrestrlcted funds General 71.479 (63.965) 7.514 Restrl£ted fuud8 SympDSiunJ GDUK Helpline 5,740 (146) 5,594 TOTAL FUIYDS PA8e 15 continued... CENE PEOPLE Notes to the Flnanelal Statements- eolltinued for the yefir ellded 31 Mar¢h 2024 12. MOVEMENT IN FUNDS- evDtlnu¢d cO￿paratIv￿ for ￿0veMent In funds Net movement in funds At 31.3.23 At 1.4.22 Unyestrleted funds General fvnd 24.385 {14,124) 10.261 Reslrlcted funds Roald Dahl's MCC 6.715 (6.715) TOTAL FUNDS Compar8live net movement in ￿tsd8, included in the 81Jove ar¢ follows.. Incoming rc50llrce5 Resource$ ¢xpended Mov¢m¢nt in fimds Unrestrfetcd funds Generdl fund 106.008 (120,132) (14.124) Restrltted funds Symposium RoAld Dahl's MCC 2,000 {2,000) TOTAL FUNDS 108 008 128 847 13. EMPLOYEE BENEFrr OBLIGATIONS Th¢ clwity operates a der￿ed Contribution pension sch£itte. The asscts of the sch¢m¢ 4r¢ held $ep&rately from those of ih¢ ¢h8rity in illd6pendEntly administeted funds. The pension costs charge represents cotttributions payable by the group to the ￿ndS and amounted to £3,986 {2023.. £5.920J. Cont¥ibutions totalling £436 (2023: £272) were payabl¢ to the fvDds at the yeor end and Are included in credithrs. T]ie expctt$c and liAbi15ty have been re¢o8nised in unrestricted funds. 14. RELATED PARTY DISCLOSURES Tlw¢w¢r¢ no relat¢dpaTty transaclioiis for the year ￿ded 31 Mar¢h 2024. Page 16 ontÈnucd... GENE PEOPLE Noteg to the Fillhn¢lAI Ststtments- contlnued for the ytsr ended 31 March 21124 IS. COMPANY STATUS The chatity is a private company limited by guarantee. The membeTS of the Company are the tNstees named on page l. l]J tbe event of the charity b¢ing wound up Ibe liability in respect of the guarantee is IiEnited to £1 per member of Ihe d)arity. Pa8e 17